Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.00    -5.00 (-6.67%)
Bid:
70.00
Ask:
72.00
Spread: 2.00 (2.857%)
Market Cap: £318.58m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Avacta Group News

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning
8 Apr 2022

AIM WINNERS & LOSERS: Sensyne Health drops amid AIM delisting warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Avacta joint venture to collaborate with Chinese biological company
8 Apr 2022

Avacta joint venture to collaborate with Chinese biological company

(Alliance News) - Avacta Group PLC said on Friday its joint venture has found a Chinese collaborator to develop new biologic drugs.

IN BRIEF: Avacta widens annual loss on research, manufacturing costs
6 Apr 2022

IN BRIEF: Avacta widens annual loss on research, manufacturing costs

Avacta Group PLC - Cambridge, England-based drug developer and diagnostics company - Posts widened loss in 2021. Pretax loss expands to GBP29.2 millio...

Avacta offloads animal health unit in £2.3m deal
16 Mar 2022

Avacta offloads animal health unit in £2.3m deal

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Av...

Avacta sells veterinary division to Vimian for up to GBP2.3 million
16 Mar 2022

Avacta sells veterinary division to Vimian for up to GBP2.3 million

(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.

Avacta moves to next dose in first-in-human chemotherapy trial
3 Feb 2022

Avacta moves to next dose in first-in-human chemotherapy trial

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubici...

Avacta shares up 12% after chemotherapy drug advances to next stage
3 Feb 2022

Avacta shares up 12% after chemotherapy drug advances to next stage

Avacta shares up 12% after chemotherapy drug advances to next stage

Avacta Group selects second pro-drug candidate
18 Jan 2022

Avacta Group selects second pro-drug candidate

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had...